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Abstract
The incidence of esophageal adenocarcinoma (EAC) has risen significantly over recent decades. Although survival has 
improved, cure rates remain poor, with <20% of patients surviving 5 years. This is the first study to explore methylome, 
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transcriptome and ENCODE data to characterize the role of methylation in EAC. We investigate the genome-wide 
methylation profile of 250 samples including 125 EAC, 19 Barrett’s esophagus (BE), 85 squamous esophagus and 21 normal 
stomach. Transcriptome data of 70 samples (48 EAC, 4 BE and 18 squamous esophagus) were used to identify changes 
in methylation associated with gene expression. BE and EAC showed similar methylation profiles, which differed from 
squamous tissue. Hypermethylated sites in EAC and BE were mainly located in CpG-rich promoters. A total of 18 575 CpG 
sites associated with 5538 genes were differentially methylated, 63% of these genes showed significant correlation between 
methylation and mRNA expression levels. Pathways involved in tumorigenesis including cell adhesion, TGF and WNT 
signaling showed enrichment for genes aberrantly methylated. Genes involved in chromosomal segregation and spindle 
formation were aberrantly methylated. Given the recent evidence that chromothripsis may be a driver mechanism in EAC, 
the role of epigenetic perturbation of these pathways should be further investigated. The methylation profiles revealed two 
EAC subtypes, one associated with widespread CpG island hypermethylation overlapping H3K27me3 marks and binding 
sites of the Polycomb proteins. These subtypes were supported by an independent set of 89 esophageal cancer samples. The 
most hypermethylated tumors showed worse patient survival.
Introduction
The incidence of esophageal adenocarcinoma (EAC) has risen 
>600% in the last 30 years (1). EAC has a poor outcome with only 
13–20% of patients surviving 5 years (2). Barrett’s esophagus (BE) 
is a precancerous precursor of EAC (3). Previous studies have 
made significant inroads into identifying the common somatic 
point mutations (1,4), copy number alterations (1), mutational 
signatures (5) and high incidence of genomic catastrophes (6) 
associated with EAC. Aberrant DNA methylation is a known 
hallmark of cancer, but genome-wide patterns of DNA methyla-
tion in EAC are yet to be fully characterized. It is well established 
that tumors arise through the accumulation of genetic and epi-
genetic aberrations and that these patterns of somatic changes 
differ from cancer to cancer. DNA methylation mostly occurs at 
cytosine residues in the CG dinucleotides context (CpG sites), 
genomic regions rich in these CpG sites are termed CpG islands 
(7). Aberrant methylation has been implicated in tumor initia-
tion and progression in several cancer types, with hypermeth-
ylation of CpG islands and promoter regions associated with 
transcriptional silencing of tumor suppressor genes. Conversely, 
hypomethylation is associated with overexpression of onco-
genes and genomic instability, although the mechanisms are yet 
to be completely understood (8).
In BE and EAC, DNA methylation studies have been limited 
to a small number of CpG sites (up to 27 578) (9–12) and focused 
on identifying differentially methylated sites. Although these 
studies suggest that DNA methylation is an important and early 
event in the development and progression of EAC, further char-
acterization of the genomic context in large cohorts remains 
less explored. Considering that epigenetic regulation adds an 
extra layer of complexity in cancer development, further studies 
to gain more insight about the landscape of DNA methylation 
in EAC are required to better understand this complex disease.
In this study, we explore methylome, transcriptome and 
ENCODE data to characterize the role of DNA methylation in 
EAC. We also assessed whether genome-wide methylation pat-
terns confer new insights into tumorigenesis and the potential 
for patient stratification that might be relevant for future per-
sonalized treatment.
Material and methods
Cohort
Written informed consent was obtained from all patients enrolled in 
this study, with approval from the Princess Alexandra Hospital and QIMR 
Berghofer Medical Research Institute research ethics committees (PAH-
HREC-2007/068, HREC/10/QPAH/152, HREC/11/QPAH/529 and QIMRP514).
A total of 250 samples were used: 125 EAC, 19 BE and 85 nontumor 
squamous esophagus (NSE), which include 64 esophageal squamous 
mucosa at least 5 cm proximal to BE (n  =  2) or EAC (n  =  62), 11 control 
samples (biopsies of squamous esophagus from healthy individuals), 10 
nondysplastic squamous esophageal mucosa from patients with gastroe-
sophageal reflux disease and 21 gastric tissue (>5 cm distal to EAC).
Sample preparation
Tissue samples were either obtained as fresh-frozen sections (snap fro-
zen in liquid nitrogen) or from research endoscopic biopsies collected in 
RNAlater (LifeTechnologies). Biopsies were directly placed in RNAlater and 
stored at 4°C for 48 h then tissue was removed from solution and stored 
at −70°C.
Fresh-frozen tumors and biopsies were assessed by an experienced 
gastrointestinal pathologist and classified based on the American Joint 
Committee on Cancer staging system. From each frozen sample, a 7 µm 
section was used to make a hematoxylin and eosin slide, followed by two 
30 µm sections for DNA extraction; this was repeated to obtain a mini-
mum of six unstained sections with serial hematoxylin and eosin. The 
hematoxylin and eosin slides were used to assess tumor percentage and 
guide macrodissection. Histopathology review of biopsy samples was 
carried out on an immediately adjacent biopsy at the same esophageal 
level to confirm the presence of BE or EAC. Samples with a minimum of 
50% tumor tissue as estimated by the pathologist were included in the 
study. DNA and RNA were extracted using the phenol–chloroform–isoamyl 
alcohol method (13). In addition, for 22 tumor/matched squamous pairs, 
DNA and RNA were extracted using AllPrep DNA/RNA Mini Kits (Qiagen, 
Valencia, CA). DNA was quantified using a Qubit® dsDNA BR Assay Kit 
(Invitrogen, Carlsbad, CA).
Bisulfite conversion and 450K methylation arrays
Genomic DNA (500 ng) was bisulfite converted using EZ DNA methyla-
tion Kits (Zymo Research) according to the manufacturer’s protocol for 
Illumina Methylation arrays. Bisulfite converted DNA was whole genome 
amplified and hybridized to Infinium Human Methylation 450K BeadChips 
(Illumina) according to the manufacturer’s protocol. Arrays were scanned 
using an iScan (Illumina). GenomeStudio v 2011.1 (Illumina) with meth-
ylation module (v 1.6.1) was used to process the raw image data.
Methylation data were background subtracted in GenomeStudio and 
normalized by beta-mixture quantile normalization to adjust for the type 
II bias. Normalization was done using the wateRmelon Bioconductor R 
Abbreviations 
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CIMP CpG island methylator phenotype 
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FDR false discovery rate
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package (14). All samples were of high quality, with >85% of probes having 
a detection P value <0.05. Data were filtered to remove probes located on X 
and Y chromosomes (n = 11 713), probes with >1 missing value (n = 33 144), 
probes with single-nucleotide polymorphisms in the CpG site or in the last 
10 bases of the probe, probes which mapped to repeats (n = 67 152) (15,16) 
and probes with detection P value >0.05 in more than 25% of samples 
(n = 7). A total of 372 817 probes were used for analysis. The methylation 
array data have been deposited in the Gene Expression Omnibus (acces-
sion number: GSE72874).
Gene expression profiling
RNA was obtained from 70 samples, 48 EAC, 4 BE and 18 squamous 
esophagus from EAC patients (Supplementary Table  1, available at 
Carcinogenesis Online). Total RNA (500 ng) was amplified and labeled 
using an Illumina TotalPrep RNA Amplification Kit (LifeTechnologies). 
Amplified RNA (750 ng) was hybridized to Illumina human HT12 (V4) 
arrays following the manufacturer’s protocol and scanned with an iScan 
(Illumina). The intensities were extracted using the GenomeStudio soft-
ware (Illumina) and background corrected, log2-transformed and quan-
tile normalized using Lumi package (17). The gene expression array data 
have been deposited into the Gene Expression Omnibus (accession num-
ber: GSE72874).
TCGA methylation data of stomach, esophageal and 
colon cancer
Publically available 450K methylation data of 395 stomach adenocarci-
nomas, 295 colon adenocarcinomas and 185 esophageal cancers [89 EAC 
and 96 esophageal squamous cell carcinomas (ESCC)] were obtained from 
the TCGA Data Portal (https://tcga-data.nci.nih.gov/) on 10 December 
2015 (18,19). Level 1 DNA methylation data (HumanMethylation450) 
obtained from TCGA (tcga-data.nci.nih.gov/tcga/) was imported into R 
using the minfi (20) package, along with the EAC dataset generated in-
house. The raw methylation values were background corrected using 
the minfi function preprocess Illumina. Methylation data were qual-
ity controlled and normalized with beta-mixture quantile as described 
above. Epstein–Barr virus information for stomach tumors was obtained 
from http://gdac.broadinstitute.org/runs/awg_stad__2013_09_30/
samples_summary_report/.
Data analysis
Differentially methylated probes in EAC and BE
Differentially methylated probes in EAC were identified using linear 
mixed effect regression models, which included EAC diagnoses (yes/no) as 
a fixed effect predictor and patient as a random effect (beta value = EAC 
diagnoses + patient). In this analysis, 125 tumors were compared with 85 
NSE. A second linear mixed effect regression model identified methylation 
changes associated with BE by using BE status (yes/no) as a fixed predic-
tor and patient as a random effect (beta value = BE status + patient). This 
analysis compared 19 BE with 85 NSE samples. Methylation differences 
between 125 tumor and 19 BE were identified for each probe using linear 
regression (beta value = sample type BE or EAC).
Clustering of data
Methylation data of EAC, BE and NSE were grouped using unsupervised 
hierarchical clustering (Ward’s method, Euclidian distance) based on the 
top 5000 most variable probes across three sample types. Hilbert-curve 
transformation was used to identify regions of the genome that contained 
clusters of differential methylation, which allows visualization of meth-
ylation data in a 2D plot, while preserving genome locality.
Pathway analysis
To determine potential biological relevance of aberrant methylation 
in EAC and BE, pathway analyses were performed using the MetaCore 
package (Thomson Reuters). Genes with promoter-associated differen-
tial methylation [false discovery rate (FDR) < 0.01 and mean beta value 
difference ≥ 0.20] between EAC or BE and NSE were used for pathway 
analysis. The relationship between probes and genes was obtained 
using the vendor annotation (Illumina). Pathways with FDR <0.001 are 
reported.
Correlation of methylation and gene expression data
Methylation and gene expression probes were mapped using the vendor 
lookup table. Pearson correlations were calculated and correlation P val-
ues were corrected for FDR. The correlation was considered significant 
when q value <0.05.
Identification of tumor subtypes
To identify potential methylation EAC subtypes, clustering was performed 
using the 5000 most variable probes (in CpG islands) from the 125 EAC. 
Probes were not highly methylated in NSE (mean beta in NSE < 0.5) and do 
not contain missing values. To minimize the potential influence of tumor 
content of each sample or batch effects, beta values were dichotomized 
using a beta value of >0.3 as a threshold for positive DNA methylation. 
Subtypes were defined by unsupervised hierarchical clustering (Ward’s 
method, binary distance) of the dichotomized data (Supplementary 
Figure  1A, available at Carcinogenesis Online). For visualization, the 
dichotomized data were back-transformed to the original beta values 
(Supplementary Figure 1B, available at Carcinogenesis Online). To identify 
samples in the top and lowest quantiles levels of methylation, the samples 
within each subtype were ordered by the total number of hypermethyl-
ated CpGs. EAC subtypes were compared with clinical features, includ-
ing alcohol consumption, smoking status and survival (Supplementary 
Table 2, available at Carcinogenesis Online).
Methylation of CpG island methylator phenotype marker genes
Methylation status of several genes has been proposed as markers for 
the CpG island methylator phenotype (CIMP), including MLH1, CDKN2A 
and MGMT in gastric cancer (21); CACNA1G, IGF2, NEUROG1, RUNX3 and 
SOCS1 in colorectal cancer (22) and KCNK13, SLIT1, RAB31, FOXL2, B3GAT2, 
FAM78A, MYOCD, KCNC1, FSTL1 and SLC6A4 also in colorectal cancer (23). 
We computed for each of these 16 marker genes the average methylation 
of probes that showed variance in beta values across all tumors >0.03 and 
that were located in CpG-rich promoters.
ENCODE data
Differentially methylated loci (FDR < 0.01 and mean beta value difference 
≥ 0.20) were mapped to ENCODE ChIP-seq data (24,25) derived from four 
cell lines: H1-hESC, K562, NHLF and NHDF-Ad. Essentially, ChIP-seq peaks 
were downloaded from the UCSC Genome Browser using the R package 
rtracklayer (26). Peaks with a score of <600 were excluded. For each ChIP-
seq dataset, the proportion of differentially methylated sites overlapping 
with a peak was determined.
EAC, stomach and colon adenocarcinomas methylation profiles
Methylation levels of our EAC and TCGA data were clustered using unsu-
pervised clustering (Ward’s method, binary distance) using the top 5000 
most variable probes in CpG islands across all cancers. Variance was com-
puted across all tumor samples. To minimize potential influence of tumor 
cellularity and batch effects, beta values were dichotomized using a beta 
value of >0.3 as a threshold for positive DNA methylation. For visualiza-
tion, the dichotomized data were back-transformed to the original beta 
values.
Results
The clinical features for the 250 samples, which includes 19 BE 
(11 with synchronous EAC and 8 from non-EAC patients), 125 
EAC, 85 NSE (11 squamous esophagus from healthy individuals, 
10 squamous esophagus from patients with gastroesophageal 
reflux disease and 64 adjacent squamous esophagus from EAC 
or BE patients) and 21 stomach samples, are summarized in 
Supplementary Table 2, available at Carcinogenesis Online.
The methylation landscape of EAC and BE
A total of 52 590 CpG sites were differentially methylated (FDR < 
0.01 and average beta value difference ≥ 0.20) in EAC compared 
with NSE (Supplementary Table  3, available at Carcinogenesis 
Online; Figure  1A), and 50 101 sites were differentially 
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methylated in BE compared with NSE (Supplementary Table 4, 
available at Carcinogenesis Online). Interestingly, 74.5% of the 
probes aberrantly methylated in EAC were also aberrantly meth-
ylated in BE (Figure 1B). However, only 2024 sites were differen-
tially methylated between EAC and BE (Supplementary Table 5, 
available at Carcinogenesis Online). The majority of differentially 
methylated sites were hypermethylated in EAC and BE, 67 and 
65%, respectively (Figure 1C) were preferentially located in CpG 
islands and promoter regions (TSS1500, TSS200, 5′ untrans-
lated regions and first exon) (Figure 1D and E). The majority of 
Figure 1. Global overview of DNA methylation patterns in BE and EAC. (A) Range of beta value differences of differentially methylated probes (FDR < 0.01) in EAC 
compared with NSE. (B) Number of differentially methylated probes and genes in EAC and BE (FDR < 0.01 and beta value difference ≥ 0.20). (C) Number of probes dif-
ferentially methylated in EAC and BE and percentage hypomethylated and hypermethylated probes. (D) Pie charts show the percentage of hypomethylated and hyper-
methylated probes across different genomic regions (CpG islands, Shore probes located less 2 kb from CpG island, Shelf = probes located >2 k from CpG islands and 
Gene Poor Region = probes not in island or annotated genes). (E) Pie charts show the percentage of hypomethylated and hypermethylated probes at gene level [TSS1500 
and TSS200—probes located within 1500 and 200 bp from TSS, respectively; 5′ untranslated regions (UTR); first exon; Body and 3′UTR].
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hypomethylated sites were situated outside from CpG islands 
(shelf and gene poor-regions) and in the body of genes (Figure 1D 
and E). Hypermethylated sites in CpG islands were located 
closer to the transcription start site (TSS) than hypomethyl-
ated sites (P  =  10−5, Wilcoxon test) (Supplementary Figure  2A, 
available at Carcinogenesis Online). No difference was observed 
in the absolute distance to the TSS for sites hypomethylated 
or hypermethylated located outside of CpG islands; however, 
hypomethylated sites tended to be located more downstream 
of the TSS than the background distribution (Supplementary 
Figure 2B, available at Carcinogenesis Online). Hilbert-curve trans-
formation identified clusters of hypermethylated loci within the 
genome (Supplementary Figure  3, available at Carcinogenesis 
Online). The largest cluster of hypermethylated CpG sites was 
an 110 kbp region on chr2 which harbors a cluster of HOX genes 
(Supplementary Figure  4, available at Carcinogenesis Online). 
HOX proteins regulate numerous processes including apop-
tosis, differentiation, motility and angiogenesis playing an 
important role in tumorigenesis. The HOX genes cluster on chro-
mosome 2 is extensively hypermethylated in both EAC and BE 
(Supplementary Figure 4, available at Carcinogenesis Online).
Methylation patterns of the top 5000 most variable probes 
across EAC, BE and NSE were able to separate EAC and BE from 
NSE, but not EAC from BE (Figure 2). Samples clustered into three 
groups, one containing mostly NSE and two groups (Clusters 
A  and B) comprised mostly of EAC and BE. In our cohort, 
58% (n  =  11/19) of the BE samples were from patients with 
synchronous EAC; however, we saw no separation of BE sam-
ples if they were collected from patients with EAC versus with-
out EAC. The methylation profile of samples in Cluster A shows 
similarities to the methylation profile of the columnar gastric 
mucosa (stomach tissue) (Figure  2), suggesting metaplastic 
transformation of the esophageal lining from normal squamous 
epithelium into columnar epithelium, which is characteris-
tic of BE and EAC. Cluster B contains EAC and BE samples that 
are characterized by hypermethylation of sites located in CpG 
islands (Figure  2). Tumors with CpG islands hypermethylation 
were first described in colon cancer and are referred to as ‘CpG 
island methylator phenotype’ (CIMP). Therefore, Cluster B con-
tains EAC samples that show a CIMP-like methylation pattern.
Association between methylation and gene 
expression
Differentially methylated CpG sites in EAC and BE compared 
with NSE were associated with 9694 and 9519 genes, respec-
tively (Figure  1B; Supplementary Tables 3 and 4, available at 
Carcinogenesis Online). From those, 83% were differentially 
methylated in both comparisons. Previously, 274 genes were 
reported as aberrantly methylated in EAC and/or BE meth-
ylation studies (9–11,27–37), of which 245 (89.4%) were also 
aberrantly methylated in our cohort (Supplementary Table  6, 
available at Carcinogenesis Online). We combined methylation 
and gene expression data for 70 samples (4 BE, 18 squamous 
esophagus from EAC patients and 48 EAC). In total, 52 590 CpG 
Figure 2. Unsupervised clustering of 125 EAC, 19 BE and 85 NSE (NSE includes 64 adjacent morphologically normal mucosa from patients with BE or EAC, 10 gastroe-
sophageal reflux disease and 11 control samples from healthy individuals). Cluster shows clear separation between NSE and EAC and BE, and suggests two EAC and BE 
subtypes (Clusters A and B). Rows in the heatmap represent CpG sites and columns represent samples. Heatmaps on the right side (black and white) show if location 
of CpG sites overlaps genomic features. White depicts overlap of CpG sites (probes) with ChIP-seq peaks (score > 600) for H3K27me3 histone marks and binding sites of 
SUZ12 and EZH2 in cell line H1-hESC and black indicates no overlap. Peaks of ENCODE ChIP-seq data were downloaded from the UCSC Genome Browser. Methylation 
profiles of 21 normal stomach samples are shown in a separate heatmap with CpG sites presented in the same order as in the unsupervised clustering. Methylation 
level of 16 CIMP marker genes is presented in a gray scale at the top of the hierarchical clustering. Methylation level of CIMP marker genes are represented as average 
beta value of probes that showed variance in beta values across all tumors >0.03 and that were located in CpG-rich promoters of genes.
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sites were differentially methylated in EAC compared with 
NSE; 35 045 sites were associated with genes. Of these, 18 575 
CpG sites were associated with 5538 genes expressed above the 
arrays’ detection limit. In total, 10 598 of the CpG sites (57% of 
testable sites) and 3502 genes (63%) showed significant corre-
lation between methylation and gene expression (FDR < 0.05, 
Pearson correlation) (Supplementary Tables 7 and 8, available at 
Carcinogenesis Online). These CpG sites were mainly located in 
promoter regions (53.5%), while 52% of CpG sites with a posi-
tive correlation with gene expression were located in the body 
of genes. Hypomethylated CpG sites located at promoter regions 
with positive correlation with gene expression were generally 
located further downstream of the TSS compared with nega-
tively correlated CpG sites (Supplementary Figure 5, available at 
Carcinogenesis Online).
Pathways aberrantly methylated in EAC and BE
Pathway analyses were performed using genes with promoter-
associated aberrant methylation, which comprised a total of 
6521 and 6299 genes in EAC and BE, respectively (Supplementary 
Tables 9 and 10, available at Carcinogenesis Online). Enriched 
pathways included known cancer signaling pathways, some 
previously described as aberrantly methylated in EAC: cell adhe-
sion, regulation of epithelial-to-mesenchymal transition and 
TGF and WNT signaling.
The highest ranked pathway affected by aberrant meth-
ylation, which has not previously been described in EAC, was 
neurophysiological process dynein–dynactin motor complex in 
axonal transport in neurons (Supplementary Table 9, available at 
Carcinogenesis Online), members of this pathway are involved in 
the neurotrophin–Trk signaling. Other members of the highest 
ranked pathway in EAC are involved in the regulation of chromo-
somal segregation and spindle assembly. Some of these genes 
were also aberrantly methylated in BE (Supplementary Table 8, 
available at Carcinogenesis Online). We identified 34 genes aber-
rantly methylated reported previously to be involved in spin-
dle assembly and chromosome segregation (Supplementary 
Table 11, available at Carcinogenesis Online). Twenty-three out 34 
genes showed detectable expression (detected in at least 20% 
of the samples) and 12/23 genes showed significant correlation 
between methylation levels and gene expression (FDR < 0.05) 
(Supplementary Table 12 and Supplementary Figure 6, available 
at Carcinogenesis Online). Here, members of the WNT signal-
ing pathway were also aberrantly methylated (Supplementary 
Table 13, available at Carcinogenesis Online), and some showed 
significant correlation with gene expression (Supplementary 
Tables 13, 14 and Supplementary Figure  7, available at 
Carcinogenesis Online).
Tumor subtypes within EAC
Clustering of NSE, BE and EAC suggested two groups of BE and 
EAC (Clusters A and B; Figure 2). To better understand the EAC 
groups, we performed unsupervised clustering of EAC sam-
ples (n  =  125) using the 5000 most variable probes located in 
CpG islands (Figure  3A). Unsupervised clustering resulted in 
two clearly distinct cluster (Supplementary Figure  1, available 
at Carcinogenesis Online; Figure  3A), which confirmed the two 
EAC molecular subtypes observed in Figure  2. The CIMP-like 
group is characterized by extensive hypermethylation of CpG 
islands with hypermethylation of CIMP marker genes identi-
fied in other studies (Figure 3A). Methylation was higher in the 
CIMP-like EACs (Figure  3B) and showed a strong enrichment 
for hypermethylation in CpG islands (P < 10−15) when compared 
with non-CIMP tumors (Supplementary Figure  8, available at 
Carcinogenesis Online). Extensively hypermethylated EACs tend 
to have poorer patient survival (Figure  3C and D). The most 
hypermethylated tumors (n  =  29, subgroup of the CIMP-like 
tumors) showed a trend of worse patient survival (P  =  0.09) 
compared with the least hypermethylated (n = 29, subgroup of 
the non-CIMP tumors) (Figure  3C). The most hypermethylated 
tumors did show a significantly worse patient survival when 
compared with all other tumors (n = 94) (P = 0.039) (Figure 3D), 
an observation that requires further validation in other cohorts.
Differentially methylated sites in EAC were mapped to his-
tone marks and transcription factor binding sites identified in 
embryonic stem cells (H1-hESC—ENCODE) (25). The CIMP-like 
subtype showed a bias for hypermethylation of loci overlapping 
H3K27me3 histone marks (P < 10−15) and binding sites of EZH2 
(P < 10−15) and SUZ12 (P < 10−15) in embryonic stem cells (H1-hESC) 
(Figure 3 and Supplementary Figure 8, available at Carcinogenesis 
Online). This enrichment was weaker in non-CIMP tumors 
(Supplementary Figure  8, available at Carcinogenesis Online). 
Similar results were obtained comparing Chip-Seq data for three 
other cell lines K562, NHLF and NHDF-Ad (data not shown).
EAC, colon and stomach adenocarcinomas show 
similarities in methylation profiles
A meta-analysis of our EAC data (n = 125) and TCGA data from 
colon (n = 295), stomach (n = 395) adenocarcinomas and esopha-
geal cancers (n = 185, 89 EAC and 96 ESCC) indicated that these 
gastrointestinal cancers may share a similar hypermethylation 
signature independent of their site of origin along the gastroin-
testinal tract (Figure 4). EAC, stomach and colon cancer formed 
two broad molecular subgroups, the first group contained CIMP-
like tumors with extensive hypermethylation of CpG islands 
and hypermethylation of CIMP marker genes (Figure 4). Almost 
all CIMP-like EACs (68 out of 72) in our initial analysis (Figure 3) 
were members of this group. This supports the presence of a 
CIMP phenotype in EAC. The presence of a CIMP-like subtype in 
EAC was replicated using 89 EACs from TCGA (Figure 4). From 
89 TCGA EAC samples, 74% showed high methylation of CIMP 
markers and cluster with CIMP-like tumors identified in Figure 3. 
In contrast, all 96 ESCC tumors from TCGA clustered with non-
CIMP EAC tumors most in a separate cluster (Cluster A), sug-
gesting no evidence of CIMP phenotype in ESCC. In accordance 
with the results obtained for our samples (Figure 3), the CIMP-
like subtype showed a strong enrichment for hypermethylation 
of CpG sites overlapping H3K27me3 histone marks and binding 
sites of the Polycomb complex 2 proteins. Clustering revealed 
several subgroups of tumors. Interestingly, EAC and stomach 
cancer showed a more similar methylation pattern (subclusters 
A, B, D and F in Figure 4) than colon tumors, which formed two 
separate subclusters (Clusters C and E). This may reflect the tis-
sue of origin of this cancer.
Discussion
EAC is treated as a single disease; however, increasing evi-
dence suggests that EAC is complex with different molecu-
lar subtypes. We and others have shown that EAC tumors 
show a wide range of mutation rates (1,5,6), differences in 
the burden of copy number and structural variations (1,6) and 
approximately one third of EAC tumors present evidence of 
chromothripsis (6). But the role of DNA methylation in EAC 
tumorigenesis is poorly understood and needs further explo-
ration. Here, we performed the first genome-wide methyla-
tion study of EAC and its impact on gene expression to better 
understand this complex disease.
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EAC and BE presented hypermethylation of sites located 
CpG islands and promoter regions when compared with squa-
mous esophagus. Although the majority of hypomethylated 
CpG sites were located outside of CpG islands and in the body 
of genes, patterns reported previously in other cancers (21,38). 
Unsupervised clustering showed good separation between 
squamous esophagus and BE and EAC, but not between EAC 
and BE, confirming previous reports that aberrant methylation 
is an early event in metaplasia–dysplasia–neoplasia progression 
(9–12).
Pathway analysis identified enrichment of known can-
cer signaling pathways previously described as aberrantly 
Figure 3. Unsupervised clustering of 125 EAC using methylation levels of the 5000 most variable probes located in CpG islands. (A) Heatmap suggests two subtypes: 
CIMP-like with high frequency of hypermethylated sites overlapping histone marks H3K27me3 and binding sites of EZH2 and SUZ12. CIMP-like also showed high levels 
of methylation associated to CIMP marker genes identified in other cancers. Rows in the heatmap represent CpG sites and columns represent samples. Methylation 
of 16 CIMP marker genes is presented in a grey scale at the top of the hierarchical clustering. Methylation of CIMP marker genes is represented as average beta value 
of probes that showed variance in beta values across all tumors >0.03 and that were located in CpG-rich promoters of genes. Heatmaps in the right side (black and 
white) show location of CpG sites in the genome. Overlap of CpG sites with ChIP-seq peaks (score > 600) for H3K27me3 histone marks and binding sites of SUZ12 and 
EZH2 is depicted in white and black indicates no overlap. The heat map in green to brown scale represents the percentage of hypermethylated probes that overlap with 
H3K27me3 histone marks and binding sites of SUZ12 and EZH2. Average methylation of NSE and stomach samples are shown in a separate heatmap (left) with CpG 
sites presented in the same order as in the unsupervised clustering. (B) Scatterplot comparing methylation in CIMP-like and non-CIMP EACs. Each dot represents the 
average beta value of probes hypermethylated in EAC compared with NSE (FDR < 0.01 and average beta value difference ≥ 0.20) in the CIMP-like versus the non-CIMP 
subtype. Methylation is generally higher in CIMP-like than in the non-CIMP tumors. (C) Kaplan–Meier plot of overall survival comparing the top quantile most hyper-
methylated tumors (n = 29 in blue) to the lowest quantile tumors with least hypermethylation (n = 29 in red). (D) Kaplan–Meier plot of overall survival comparing the 
top quantile most hypermethylated tumors (n = 29 in blue) to all other tumors (n = 94 in red).
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methylated in EAC: cell adhesion (9,11), regulation of epithelial-
to-mesenchymal transition and TGF and WNT signaling (11). 
Here the top pathway affected by aberrant methylation in EAC 
was ‘neurophysiological process dynein–dynactin motor com-
plex in axonal transport in neurons’. Members of this pathway 
are involved in the neurotrophin–Trk signaling, which was previ-
ously reported to be aberrantly methylated in EAC (11). Mutations 
and rearrangements of TRK genes are only sporadically seen in 
human cancers, but recent studies indicate that expression of 
TrkB contributes to tumor pathology (39). Other members of 
the highest ranked pathway which were aberrantly methylated 
in EAC are involved in chromosomal segregation and spindle 
assembly, these include the BUB3, AURKA, DYNC1I1 and DCTN2 
and CHFR genes. CHFR is involved in the mitotic G2-M checkpoint 
and has been reported hypermethylated in lung cancer (40), EAC 
(41) and gastric cancer (42). Here, members of the WNT signal-
ing pathway were also aberrantly methylated, inhibition of WNT 
signaling has recently been reported to increase microtubule 
assembly rates, abnormal mitotic spindle formation and induc-
tion of aneuploidy and generation of lagging chromosomes (43). 
The complexity and current knowledge of the mitotic apparatus 
has been reviewed by Vitale et al. (44), who highlighted that the 
molecular mechanisms involved in mitotic aberration, cell death 
and genomic stability are still largely elusive. They suggested 
that cancer cells develop strategies to breach aneuploidy, thus 
avoiding mitotic catastrophes and death. Mutations of several 
mitotic checkpoint proteins have been found in different cancers 
but are not common. Epigenetic events are thought to be one of 
the mechanisms to avoid cell death after mitotic catastrophes 
(44) and interestingly alteration in the levels of expression of the 
mitotic checkpoint genes is more common (45). Therefore, we 
suggest that epigenetic dysregulation may account, in part, for 
gene expression changes observed in those pathways. It is known 
that EAC tumors contain a high frequency of chromosomal rear-
rangements, aneuploidy (46,47) and chromosome catastrophes 
that result in amplification of oncogenes (6). Therefore, aberrant 
methylation of genes involved in chromosomal segregation and 
spindle assembly deserves further investigation due their role in 
the mitotic apparatus that can lead to chromosomal instability 
and chromothripsis (48,49).
Identification of EAC subtypes may give important insights 
into tumorigenesis and represents an important step toward 
Figure 4. Unsupervised clustering of 125 EAC (present study) and TCGA 450K methylation data from 395 stomach, 295 colon adenocarcinomas and 185 esophageal 
cancers (89 EAC and 96 ESCC). Mean methylation of nontumor squamous esophagus (n = 64) and TCGA data of nontumor stomach (n = 2) and nontumor colon (n = 28) is 
given as separate heatmap on the left with probes in the same order as in the unsupervised clustering. Stomach adenocarcinomas and EAC showed strikingly similar 
methylation profiles and formed mixed clusters (B, D and F). ESCC tumors formed mainly a separate (Cluster A), and no ESCC clustered with extensively hypermethyl-
ated tumors (CIMP-like tumors). Colon adenocarcimas displayed a more distinct methylation profile and formed separate clusters (C and E). Clusters D, E and F showed 
a group of tumors with extensive CpG island hypermethylation suggesting a potential common mechanism independent of tissue of origin. Methylation data were 
grouped using unsupervised clustering (Ward’s method, binary distance) based on the top 5000 most variable probes located in CpG islands. Variance was computed 
across all tumor samples. To minimize potential influence of tumor cellularity or batch effects, beta values were dichotomized using a beta value of >0.3 as a threshold 
for positive DNA methylation. After clustering the dichotomized values were back-transformed to the original beta values. Rows in the heatmap represent CpG sites 
and columns represent samples. Heatmaps in the right side (black and white) show location of CpG sites in the genome. Overlap of CpG sites with H3K27me3 histone 
marks and binding sites of SUZ12 and EZH2 is depicted in white and black indicates no overlap. Methylation of 16 CIMP marker genes is presented in a gray scale at 
the top of the hierarchical clustering, which are represented as average beta value of probes that showed variance in beta values across all tumors >0.03 and that were 
located in CpG-rich promoters of genes.
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patient-specific personalized treatment. Here, we identified two 
groups of tumors, one of which showed high levels of methyla-
tion in CpG islands similar to the CIMP phenotype identified 
in other cancers. EAC CIMP-like showed enrichment of hyper-
methylation of sites overlapping the H3K27me3 histone mark 
and binding sites of the Polycomb complex 2 (PRC2) proteins. 
This pattern was previously described in gastric cancer (21) and 
could suggest that DNA methylation may replace Polycomb-
based repression near key genes possibly reducing their regula-
tory plasticity (50). In other cancers, the CIMP phenotype has 
been associated to somatic mutation such BRAF in colorectal 
cancer (23) and IDH1 in gliomas (51). In gastric cancer, two CIMP 
subtypes have been identified, one of which was associated with 
Epstein–Barr virus-positive tumors and the other CIMP group 
associated with microsatellite instability (18). Future multi-omic 
studies of EAC are required to show an association of the CIMP-
like phenotype and other biological features. However, our data 
suggested that tumors with extensive CpG island hypermeth-
ylation are associated with poorer clinical outcome.
In summary, this study described the methylation land-
scape of EAC and its impact on gene expression, these data sug-
gest an orchestrated epigenetic deregulation with potentially 
a much stronger role in EAC carcinogenesis than anticipated. 
Methylation patterns revealed two subtypes, one similar to the 
CIMP phenotype which was potentially associated with worse 
clinical outcome. These findings provide new insights into 
the contribution of epigenetics to EAC carcinogenesis. Further 
molecular characterization of the subtypes identified here 
with integration of additional information such copy number 
changes, structural variants and somatic mutations may lead to 
better stratification of EAC subtypes with clinical implications.
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